Feedback
Settings

Settings

Goto Application

17,026 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(PTJWIQPHWPFNBW-GBNDHIKLSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 1,703
1.WO/2025/119346ANP-DEPENDENT ANTIBODIES
WO - 12.06.2025
Int.Class C07K 16/44
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
44against material not provided for elsewhere
 Appl.No PCT/CN2024/137508 Applicant LANOVA MEDICINES LIMITED Inventor LI, Runsheng
Provided are antibodies capable of binding an antigen in an adenine nucleotide-dependent manner. Examples of adenine nucleotides include ATP, ADP and AMP, which are frequently present in tumor microenvironment at much higher concentrations in normal tissues. Such antibodies, if designed to target a tumor associated antigen or immune checkpoint molecule, can target tumor tissues more specifically than conventionally antibodies and thus have improved therapeutic index.
2.WO/2025/122721CHIMERIC PROTEINS AND USES THEREOF
WO - 12.06.2025
Int.Class C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
 Appl.No PCT/US2024/058632 Applicant SHATTUCK LABS, INC. Inventor SCHREIBER, Taylor
The present disclosure relates to, inter alia, compositions and methods, including heterologous chimeric proteins that find use, inter alia, in the treatment of diabetes, obesity, or metabolic syndrome.
3.WO/2025/120097RNA-BASED STRATEGIES FOR DENDRITIC CELL REPROGRAMMING AND USES THEREOF
WO - 12.06.2025
Int.Class C12N 5/0784
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0784Dendritic cells; Progenitors thereof
 Appl.No PCT/EP2024/084945 Applicant ASGARD THERAPEUTICS AB Inventor ROSA, Fábio Alexandre Fiúza
The present invention relates to compositions comprising RNAs, uses thereof, and RNA-based gene expression methods for reprogramming cells to type 1 conventional dendritic cells or antigen-presenting cells. The invention further relates to cells, reprogrammed cells, and uses thereof.
4.WO/2025/122062MESSENGER RNA VACCINES TARGETING DENGUE VIRUS PROTEINS
WO - 12.06.2025
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No PCT/SG2024/050773 Applicant NATIONAL UNIVERSITY OF SINGAPORE Inventor WATANABE, Satoru
Disclosed is a construct for preventing antibody-dependent enhancement of dengue virus infection, comprising: (a) a ribonucleic acid encoding a non-structural protein of a dengue virus wherein each of the uridine residues of the ribonucleic acid encoding a non-structural protein of a dengue virus is replaced with pseudouridine; (b) a 7-methylguanylate cap; (c) a 5' untranscribed region preferably comprising a kozak consensus ribonucleic acid sequence; (d) a 3' untranscribed region; and (e) a poly A tail and a method for using the construct to prevent antibody-dependent enhancement of dengue virus infection
5.WO/2025/119162METAPNEUMOVIRUS (MPV) VACCINE
WO - 12.06.2025
Int.Class C12N 15/45
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
45Paramyxoviridae, e.g. measles virus, mumps virus, Newcastle disease virus, canine distemper virus, rinderpest virus, respiratory syncytial viruses
 Appl.No PCT/CN2024/136380 Applicant SHENZHEN SHENXIN BIOTECHNOLOGY CO., LTD. Inventor LI, Linxian
Provided is a metapneumovirus (MPV) vaccine. Specifically, provided is a nucleic acid comprising a polynucleotide for encoding a mutant of an MPV F protein, compared with a wild-type MPV F protein, the mutant comprises a disulfide bond mutation.
6.WO/2025/122628CIRCULARIZED RNAS AND METHODS OF MAKING THE SAME
WO - 12.06.2025
Int.Class C12Q 1/6806
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction assay
 Appl.No PCT/US2024/058479 Applicant HELIX NANOTECHNOLOGIES INC Inventor SAUCEDA, Arianna Lizeth Lopez
The present disclosure provides methods of circularizing RNA using RNA ligase. The present disclosure also provides polyribonucleotides that can be useful in such methods. Such polyribonucleotides can comprise a 5' end comprising a 5'- most nucleotide, a 3' end comprising a 3'- most nucleotide, a first hybridization region and a second hybridization region, wherein the ribonucleotide sequence of the second hybridization region is a reverse complement of the ribonucleotide sequence of the first hybridization region.
7.WO/2025/121444COMBINATION THERAPY INVOLVING BISPECIFIC BINDING AGENTS BINDING TO CLDN18.2 AND CD3 AND ANTI-VEGFR2 ANTIBODIES
WO - 12.06.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/JP2024/080220 Applicant ASTELLAS PHARMA INC. Inventor NAKANO, Kazue
The present invention provides a combination therapy involving bispecific binding agents comprising two binding domains binding to CLDN18.2 and a binding domain binding to CD3 and antibodies that binds to VEGFR2. The combination therapy is effective in treating cancer involving cancer cells expressing CLDN18.2.
8.WO/2025/120230METHOD OF PRODUCING LEUKOCYTES EXPRESSING ARTIFICIAL ANTIGEN RECEPTORS
WO - 12.06.2025
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
 Appl.No PCT/EP2024/085326 Applicant T-CURX GMBH Inventor GRAWUNDER, Ulf
The present invention relates to a lipid nanoparticle (LNP) suitable for transfecting a leukocyte, which nanoparticle comprises an mRNA encoding for a transposase enzyme, and a DNA encoding for an antigen receptor.
9.WO/2025/121445COMBINATION THERAPY INVOLVING BISPECIFIC BINDING AGENTS BINDING TO CLDN18.2 AND CD3 AND AGENTS STABILIZING OR INCREASING EXPRESSION OF CLDN18.2
WO - 12.06.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/JP2024/080221 Applicant ASTELLAS PHARMA INC. Inventor TANAKA, Hiroaki
The present invention provides a combination therapy involving bispecific binding agents comprising two binding domains binding to CLDN18.2 and a binding domain binding to CD3 and agents stabilizing or increasing the expression of CLDN 18.2. The combination therapy is effective in treating cancer involving cancer cells expressing CLDN18.2.
10.WO/2025/120866COMBINATION THERAPY INVOLVING BISPECIFIC BINDING AGENTS BINDING TO CLDN18.2 AND CD3 AND AGENTS STABILIZING OR INCREASING EXPRESSION OF CLDN18.2
WO - 12.06.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/JP2023/044949 Applicant ASTELLAS PHARMA INC. Inventor TANAKA, Hiroaki
The present invention provides a combination therapy involving bispecific binding agents comprising two binding domains binding to CLDN18.2 and a binding domain binding to CD3 and agents stabilizing or increasing the expression of CLDN18.2. The combination therapy is effective in treating cancer involving cancer cells expressing CLDN18.2.
# -